Tolerogenic nanoparticles impacting B and T lymphocyte responses delay autoimmune arthritis in K/BxN mice
A Srivastava, BM Arlian, L Pang… - ACS chemical …, 2021 - ACS Publications
Current treatments for unwanted antibody responses largely rely on immunosuppressive
drugs compromising overall immunity. New approaches to achieve antigen-specific …
drugs compromising overall immunity. New approaches to achieve antigen-specific …
[HTML][HTML] Tolerogenic nanoparticles impacting B and T lymphocyte responses delay autoimmune arthritis in K/BxN mice
A Srivastava, BM Arlian, L Pang, TK Kishimoto… - ACS chemical …, 2021 - ncbi.nlm.nih.gov
Current treatments for unwanted antibody responses largely rely on immunosuppressive
drugs compromising overall immunity. New approaches to achieve antigen-specific …
drugs compromising overall immunity. New approaches to achieve antigen-specific …
Tolerogenic nanoparticles targeting B and T lymphocytes delay autoimmune arthritis in K/BxN mice
A Srivastava, BM Arlian, L Pang, TK Kishimoto… - bioRxiv, 2020 - biorxiv.org
Objective This study aims to examine the therapeutic potential of combined treatment with B
cell targeted STALs and T cell targeted PLGA-R nanoparticles in treating K/BxN mice that …
cell targeted STALs and T cell targeted PLGA-R nanoparticles in treating K/BxN mice that …
Tolerogenic Nanoparticles Impacting B and T Lymphocyte Responses Delay Autoimmune Arthritis in K/BxN Mice.
A Srivastava, BM Arlian, L Pang, TK Kishimoto… - ACS Chemical …, 2021 - europepmc.org
Current treatments for unwanted antibody responses largely rely on immunosuppressive
drugs compromising overall immunity. New approaches to achieve antigen-specific …
drugs compromising overall immunity. New approaches to achieve antigen-specific …
[PDF][PDF] Tolerogenic Nanoparticles Impacting B and T Lymphocyte Responses Delay Autoimmune Arthritis in K/BxN Mice
A Srivastava, BM Arlian, L Pang, TK Kishimoto… - scholar.archive.org
Current treatments for unwanted antibody responses largely rely on immunosuppressive
drugs compromising overall immunity. New approaches to achieve antigen-specific …
drugs compromising overall immunity. New approaches to achieve antigen-specific …
Tolerogenic Nanoparticles Impacting B and T Lymphocyte Responses Delay Autoimmune Arthritis in K/BxN Mice
A Srivastava, BM Arlian, L Pang… - ACS chemical …, 2021 - pubmed.ncbi.nlm.nih.gov
Current treatments for unwanted antibody responses largely rely on immunosuppressive
drugs compromising overall immunity. New approaches to achieve antigen-specific …
drugs compromising overall immunity. New approaches to achieve antigen-specific …
[PDF][PDF] Tolerogenic Nanoparticles Impacting B and T Lymphocyte Responses Delay Autoimmune Arthritis in K/BxN Mice
A Srivastava, BM Arlian, L Pang, TK Kishimoto… - researchgate.net
Current treatments for unwanted antibody responses largely rely on immunosuppressive
drugs compromising overall immunity. New approaches to achieve antigen-specific …
drugs compromising overall immunity. New approaches to achieve antigen-specific …
Tolerogenic nanoparticles targeting B and T lymphocytes delay autoimmune arthritis in K/BxN mice
A Srivastava, BM Arlian, L Pang, TK Kishimoto… - bioRxiv, 2020 - biorxiv.org
Objective This study aims to examine the therapeutic potential of combined treatment with B
cell targeted STALs and T cell targeted PLGA-R nanoparticles in treating K/BxN mice that …
cell targeted STALs and T cell targeted PLGA-R nanoparticles in treating K/BxN mice that …
Tolerogenic Nanoparticles Impacting B and T Lymphocyte Responses Delay Autoimmune Arthritis in K/BxN Mice
A Srivastava, BM Arlian, L Pang, TK Kishimoto… - 2020 - europepmc.org
Current treatments for unwanted antibody responses largely rely on immunosuppressive
drugs compromising overall immunity. New approaches to achieve antigen-specific …
drugs compromising overall immunity. New approaches to achieve antigen-specific …